Moclobemide in patients with
dementia and depression

by
Amrein R, Martin JR, Cameron AM
F. Hoffmann-La Roche, Ltd.,
Basel, Switzerland.
Adv Neurol 1999; 80:509-19


ABSTRACT

Moclobemide, the first reversible inhibitor of MAOA (so-called RIMA) to become widely available for clinical use, is an effective and well-tolerated antidepressant. Preclinical experiments, as well as studies in human volunteers and patients, provide evidence for the cognition enhancing effects of moclobemide. This cognition improvement, taken together with moclobemide's absence of anticholinergic effects, lack of sedation, and similarity in pharmacokinetics in young and elderly individuals, makes this drug especially appropriate for use in treatment of the elderly depressed patient.
MAO
RIMAs
Phenelzine
Brofaromine
Isocarboxazid
Tranylcypromine
MAOIs and dopamine
Moclobemide : history
Moclobemide for migraine
Moclobemide and dysthymia
Moclobemide and social phobia
Moclobemide and panic disorder
Moclobemide (Manxerix, Aurorix) : review
Moclobemide and new hippocampal neurons
Moclobemide and hippocampal neurogenesis
Genetic variation in MAO-A and human personality


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family